Clinical trial
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent…
NCT00006089 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00006089 |
|---|---|
| Title | Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer |
| Official title | A Phase II Evaluation of Trastuzumab (MoAb HER2) in Patients With Advanced, Recurrent or Persistent Endometrial Carcinoma With or Without Prior Chemotherapy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Gynecologic Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Adenocarcinoma, ERBB2 Gene Amplification, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7 |
| Intervention type | Biological, Other |
| Interventions | Laboratory Biomarker Analysis, Trastuzumab |
| Enrollment | 34 |
| Start date | Sep 18, 2000 |
| Primary completion | Sep 4, 2007 |
| Completion | Jan 31, 2010 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 31, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: